Business Context and Reporting Period
Company: Accuray Incorporated (Accuray)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: Accuray designs, develops, and sells the CyberKnife system, an image-guided robotic radiosurgery system used to treat solid tumors. The company operates globally with subsidiaries in Europe, Asia, and the Americas. As of March 31, 2011, 226 CyberKnife systems were installed at customer sites.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Mar 31, 2011 | Nine Months Ended Mar 31, 2011 | Balance Sheet (Mar 31, 2011) |
|---|---|---|---|
| Total Net Revenue | $54,747 | $147,061 | - |
| Gross Profit | $27,313 | $75,016 | - |
| Gross Margin | 49.9% | 51.0% | - |
| Operating Income (Loss) | $(526) | $(2,970) | - |
| Net Income (Loss) | $(1,160) | $(1,702) | - |
| Cash and Cash Equivalents | - | - | $57,332 |
| Short-term Investments | - | - | $85,603 |
| Total Current Assets | - | - | $236,517 |
| Total Current Liabilities | - | - | $76,805 |
| Accumulated Deficit | - | - | $(119,405) |
Liquidity: The company reported $143.0 million in cash, cash equivalents, and marketable securities as of March 31, 2011. Management believes these resources are sufficient to fund operations for at least the next twelve months.
Material Changes vs. Prior Period
- Revenue: Total net revenue increased 5% to $54.7 million for the three months ended March 31, 2011, compared to $51.9 million in the prior year period. However, for the nine-month period, revenue decreased 8% to $147.1 million from $159.8 million. The decline in the nine-month period was primarily due to a significant reduction in revenue recognized from legacy "Platinum" service plans ($4.8 million in 2011 vs. $23.9 million in 2010).
- Profitability: The company reported a net loss of $1.2 million for the quarter, compared to a net income of $2.3 million in the prior year quarter. For the nine months, the net loss narrowed to $1.7 million from $2.2 million in the prior year.
- Operating Expenses: General and administrative expenses increased 35% ($2.7 million) for the quarter, primarily driven by $2.4 million in accounting, legal, and consulting fees related to the proposed acquisition of TomoTherapy. Research and development expenses increased 20% ($1.6 million) due to increased consulting fees and clinical research studies.
- Cash Flow: Net cash used in operating activities was $9.1 million for the nine months ended March 31, 2011, an improvement from $12.4 million used in the prior year period. This was driven by a decrease in net loss and changes in working capital, though offset by a $7.8 million increase in inventories.
Guidance, Outlook, and Risks
- TomoTherapy Acquisition: On March 6, 2011, Accuray entered into a definitive agreement to acquire TomoTherapy Incorporated for approximately $268.1 million in cash and stock. The transaction is expected to close in the fourth quarter of fiscal 2011 or the first quarter of fiscal 2012, subject to regulatory approvals and shareholder votes. Management anticipates the merger will be accretive to earnings per share in fiscal year 2012.
- Siemens Alliance: The strategic alliance with Siemens AG regarding the "Cayman Products" has seen little development work and no milestone payments to date due to Siemens' internal reorganization and the impact of the TomoTherapy acquisition announcement.
- Revenue Recognition Changes: The company adopted new accounting standards (ASU 2009-13 and ASU 2009-14) in the first quarter of fiscal 2011 regarding multiple-deliverable revenue arrangements. The impact on reported revenue was deemed insignificant for the period.
- Legal Contingencies: A securities class action lawsuit was settled for $13.5 million, fully covered by insurance. A shareholder derivative lawsuit was settled for $0.8 million, also fully covered by insurance. A patent infringement lawsuit by Best Medical International remains pending, with two counts of alleged willful infringement remaining after partial dismissal.
- Risks: Key risks include the uncertainty of the TomoTherapy merger closing, potential delays in the sales and installation cycle for CyberKnife systems, reliance on single-source suppliers for critical components, and changes in third-party reimbursement rates (Medicare).
Investor Verification Checklist
- Merger Status: Verify the progress of the TomoTherapy acquisition, specifically the status of regulatory approvals and shareholder votes required for closing.
- Backlog Conversion: Review the $414.3 million backlog (as of March 31, 2011) and assess the timeline for revenue recognition, noting the long sales and installation cycles (1-2 years).
- Legacy Revenue Run-off: Confirm the trajectory of revenue from legacy "Platinum" service plans, which is expected to decrease as these contracts lapse.
- Inventory Levels: Investigate the $7.8 million increase in inventory over the nine-month period to ensure it aligns with demand forecasts and does not signal future write-downs.
- Legal Exposure: Monitor the outcome of the Best Medical International patent infringement litigation, as the company has not estimated the financial impact.